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Abstract 
Objective: To examine factors that predict glycemic control in children and adolescents with 
Type 1 diabetes in Southwestern Ontario from 1998-2008. 
Methodology: A population based cohort study was conducted using local pediatric clinical 
diabetes database (Humabase) to determine demographic and diabetes-related clinical factors 
that predict achievement of the target glycemic control under 'real world' conditions. Clinical 
parameters including the outcome (A1C level) were documented in Humabase. Socio-
economic variables were derived using Forward Sortation Area and linking it to the Census 
of Canada Data.   
Results: Factors associated with improved glycemic control were age-specific. Longer 
distance from the treatment center (OR 0.35), female gender (OR 0.45), longer diabetes 
duration (OR 1.12), and greater body mass index at diagnosis (OR 1.07) predicted 
achievement of the target glycemic control on multivariable analyses.  
Conclusions: In this regional cohort we identified factors that predict glycemic control. 
Targeted support should be considered for high risk individuals. 
 
Keywords 
Type 1 diabetes; children and adolescents; pediatric; population-based; electronic databases; 
predictors; glycemic control; A1C   
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Chapter 1 
1 Introduction  
Type 1 diabetes (T1D) is a common chronic disorder of childhood that is characterized by 
insulin deficiency resulting in chronic hyperglycemia. Chronically elevated blood glucose levels 
lead to multiple long term diabetes complications involving the eyes, kidneys, nerves, and heart 
and blood vessels. The incidence of T1D is increasing worldwide by 3-5% per year (Maahs, 
West, Lawrence, & Mayer-Davis, 2010). Despite new treatments and improvement in the 
survival rates over the past 30 years, those who are diagnosed with T1D in childhood still have 
up to a 6 fold increase in mortality compared to the general population (Secrest, Becker, Kelsey, 
LaPorte,  & Orchard, 2010).  
The complexity and intensity of T1D management in childhood continues to increase. The goal 
of diabetes management is to provide care that will result in lowest possible risk of diabetes 
complications. Intensification of insulin treatment and achievement of tight glycemic control in 
adolescent and adults with T1D prevents the onset and progression of long term complications 
such as blindness, dialysis, limb amputations, strokes and heart attacks (Diabetes Control and 
Complications Trial [DCCT] Research Group, 1993). In addition, optimal glycemic control is 
best achieved through an access to interdisciplinary pediatric diabetes health care team. The 
interdisciplinary treatment approach is a key intervention that has been shown to improve health 
outcomes (Glasgow et al., 1991) and is the current standard of pediatric diabetes care in Canada.  
Treatment goals and strategies should also give consideration to complex physiologic, 
developmental, and social needs of children and adolescence to ensure the best long-term 
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outcomes (Canadian Diabetes Association [CDA] Clinical Practice Guidelines, 2008). Diabetes 
management in childhood is clearly complex and there is more than one approach toward 
improving the metabolic control in children and adolescents with T1D. 
Optimal glycemic control in children and adolescents is essential. However, optimal glycemic 
control is difficult to achieve in the ‘real-world’. Observational population-based studies have 
indicated suboptimal levels of glycemic control worldwide despite the well-publicized results of 
the DCCT (Petitti et al., 2009; Johannesen et al, 2008; Hanberger et al, 2008; Gerstl et al, 2007). 
Surveillance and quality assurance programs on childhood diabetes provided helpful data on 
glycemic outcomes but there is a limited literature on factors responsible for the suboptimal 
glycemic levels in the ‘real-world’. In Canada, there are no studies that have examined predictive 
variables and their influence on the glycemic outcomes in the unselected population of children 
and adolescents. Therefore, improving understanding of optimal glycemic control in children and 
adolescents with T1D treated under ‘real-world’ conditions would be useful. In this thesis, we 
have explored an opportunity to assess selected predictors of optimal glycemic control under 
real-life, ‘effectiveness’ conditions through the use of a unique electronic clinical database in 
Southwestern Ontario.   
Previous research has identified a number of socio-demographic and clinical factors associated 
with better glycemic control. Factors such as gender, age, ethnicity, family structure and 
socioeconomic status, duration of diabetes and treatment approach have been found to be 
associated with glycemic control in cross sectional studies (Dorchy, Roggemans, &Willems, 
1997; Rosilio et al., 1998; Mortensen & Hougaard, 1997). However, there are only a few 
prospective studies that have assessed the predictors of long term glycemic control (Shalitin & 
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Phillip, 2011; Cutfiled et al., 2011; Johannesen et al., 2008; Hanberger et al., 2008; Gerstl et al., 
2007; Palta et al., 1996). Determining the factors that predict achievement of glycemic control in 
children and adolescents with T1D is important since it allows for identification of  high risk 
groups, promotion of early intervention, and appropriate resource allocation for this particularly 
vulnerable patient group.  
Our research goal was to assess predictors of glycemic control in children and adolescents with 
T1D using data from a large regional clinical electronic database in Ontario. This was a unique 
opportunity to study determinants of glycemic control in a geographically defined region.  All 
children newly diagnosed with T1D in the Southwestern Ontario, a region of 2.5 million people, 
are referred to Children’s Hospital, London Health Sciences Centre (CH-LHSC) specialized 
pediatric diabetes program. Therefore, our study population was highly representative of the 
region. Moreover, as there are no studies looking at the predictors of glycemic control in Canada, 
this study was the first to address this issue.  
This study is the first step of program research aimed at creating a research database and 
conducting exploratory analyses using pediatric clinical electronic data.    
Our research was set in the context of the increasing use of electronic medical records (EMR) 
and databases in diabetes research. We used, for the first time, a local pediatric clinical diabetes 
database  (Humabase) that has maintained demographic and clinical information on 
approximately 2000 pediatric T1D patients in the Southwestern Ontario since the late 1980’s.  
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1.1 Thesis Objectives 
The purpose of this study was to determine factors that are associated with glycemic control (as 
measured by the glycated hemoglobin or A1C level) in children and adolescents with T1D to 
answer the following research question: 
Are there demographic and diabetes-related clinical factors that predict 
achievement of future target glycemic control in children and adolescents with T1D 
in Southwestern Ontario? 
The three main objectives directly related to the primary research question were as follows: 
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008 
using a regional electronic clinical database for future studies in Type 1 diabetes 
Objective 2: To describe and examine social, demographic, and clinical characteristics of this 
cohort. 
Objective 3: To identify factors predictive of glycemic control in the following three age groups: 
< 6 years of age, 6-12 years, and > 12 years of age. 
.  
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Chapter 2 
2 Type 1 Diabetes in Children and Adolescents 
Chapter 2 is divided into seven sections and provides an overview relevant to this research. The 
initial part of the chapter will provide background information on T1D including the burden of 
this disease, epidemiology and pathogenesis of T1D, and a brief description of diabetes-related 
complications. It also summarizes the evidence on management including goals of glycemic 
control in children and adolescents with T1D. Next is a section presenting background literature 
on the factors predicting achievement of glycemic control in this population. The last section will 
integrate the findings and incorporate them into a discussion on quality and current standard of 
pediatric diabetes care.  
2.1   Incidence of Type 1 Diabetes 
T1D is one of the most common chronic illnesses of childhood, second only to asthma (Osgood, 
Foster, & Courtney, 2010). Globally, the incidence of T1D varies with the lowest rates in 
developing countries (e.g. China and Venezuela) and the highest rates in developed countries 
such as Finland. Importantly, the incidence rates of childhood T1D are increasing worldwide. 
The average annual incidence increase is 3% with the steepest increase in the youngest age 
groups and lower incidence areas (International Diabetes Federation [IDF], 2011). If the current 
trends continue, the incidence of T1D will double every 20 years (Daneman, 2009). Canada has 
the sixth highest incidence of T1D in children 14 years or younger in the world (IDF, 2007). The 
incidence of T1D is rising by three to five percent per year in Canada; the greatest increase has 
occurred in children aged 5 to 9 years. In Ontario, the Institute for Clinical Evaluative Science 
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(ICES) has reported an overall 17% increase in incidence of diabetes in children between 1996 
and 2000. The incidence of diabetes among Ontario children under 19 years of age was 
28/100,000 in 2000 (To, Curtis, & Daneman, 2003). Currently, over 240,000 Canadians live with 
T1D (Juvenile Diabetes Research Foundation of Canada [JDRF], 2012).  
It is particularly concerning that the incidence of T1D is increasing in the youngest age group. 
Given that children who develop diabetes early are more at risk to develop long-term 
complications, these data underline the immense personal and societal impact of T1D in the 
pediatric population. 
2.2   Pathogenesis of Type 1 Diabetes 
Type 1 Diabetes (T1D) is an autoimmune disorder characterized by destruction of the insulin 
producing pancreatic beta cells in genetically susceptible individuals. The etiology of T1D 
remains unknown. While major susceptibility genetic loci for T1D have been identified, only a 
small percentage (<5%) of individuals with genetic susceptibility develop clinical disease 
(Mehers & Gillespie, 2008; Virtanen & Knip, 2003). This is explained by a powerful influence 
of one or more environmental triggers (TEDDY Study Group, 2008). Putative triggers include 
infectious agents (eg, enteroviruses, coxsackie, congenital rubella) or components of early diet 
(cow milk protein, cereal or gluten exposure) (TEDDY study group, 2008; Maahs et al., 2010). 
Clinical diabetes develops when the continuing destruction of pancreatic beta cells finally results 
in absolute insulin deficiency (Daneman, 2006). This process results in lifelong dependency on 
daily insulin injections for survival. 
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2.2.1 Phases of Diabetes in Children and Adolescents 
Type 1 diabetes in the pediatric population is characterized by a preclinical phase, presentation, 
partial remission or honey moon phase and finally a chronic lifelong insulin dependent phase 
(International Society for Pediatric and Adolescent Diabetes [ISPAD] Clinical Practice 
Guidelines, 2009). Preclinical diabetes is the phase before presentation, during which markers of 
autoimmunity may be identified. In contrast to type 2 diabetes which can often go undiagnosed 
for months and years, the clinical onset of T1D usually follows an acute and dramatic course. 
The presentation of T1D is often complicated by diabetic ketoacidosis (DKA), a life threatening 
event. In Manitoba, the frequency of DKA at presentation of T1D in children age <18 years 
ranged from 21.8%-35.1% (2010 Winnipeg Child Health Program Annual Report, n.d.), whereas 
a European EURODIAB study reported DKA in 42% of children (Levy-Marchal et al., 2001). 
The honeymoon or partial remission period occurs soon after clinical diagnosis and initiation of 
insulin therapy. In 42-80 % percent of children and adolescents, insulin requirements decrease 
transiently following initiation of insulin treatment (Lombardo et al., 2002; Kordonouri et al., 
2008). It is suspected that remaining beta cells that are exhausted but not yet destroyed restore 
endogenous insulin production at the same time as insulin resistance decreases with the 
alleviation of hyperglycemia (Daneman, 2006; Aly & Gottlieb, 2009). The partial remission 
phase commences within days or weeks of the start of insulin therapy and may last for weeks to 
months. Lombardo and colleagues report that the mean duration of the partial remission period is 
11.7 +/- 8.9 months. In a few children and adolescents, requirements for insulin may decrease to 
the point of being able to withdraw insulin therapy temporarily and still maintain 
normoglycaemia (Hanas, Donaghue, Klingensmith, & Swift, 2006, 2009). This partial remission 
phase is always transient and progresses to the chronic phase of lifelong insulin dependence. 
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2.3   Diabetes Complications 
Long term diabetes complications are divided into microvascular and macrovascular 
complications. Microvascular complications include nephropathy, retinopathy, and neuropathy, 
while cardiovascular, cerebrovasular and peripheral vascular disease are the components of 
macrovascular complications.  
2.3.1 Nephropathy 
A declining incidence of reported complications in many areas with specialized diabetes clinics 
has been noted (Mohsin et al., 2005). Still, diabetic nephropathy is a major cause of morbidity 
and mortality among young adults with T1D (Schultzs et al., 1999).The cumulative prevalence of 
microalbuminuria (a marker of future renal failure) in childhood onset T1D is between 12-25% 
after 5-10 years of disease (Amin et al., 2008). Microalbuminuria has been shown to be highly 
predictive of progression to advanced stages of diabetic nephropathy. However, the rate of this 
progression has varied across studies with a range between 50-80% (Mogensen, 1982; Viberti, 
Jarrett, & Keen, 1982; Perkins et al., 2003).  More recent studies have shown a decline in the rate 
of progression to advanced nephropathy. In a cohort of 20,005 individuals from Finland 
diagnosed younger than 30 years of age between 1965 and 1999, Finne, Reunanen, Stenman, 
Groop, & Gronhagen-Riska (2005) reported a cumulative prevalence of end-stage renal disease 
of 2.2% at 20 years.   
2.3.2 Retinopathy and Neuropathy 
Diabetic retinopathy is the most common cause of acquired blindness in the Western world, with 
a prevalence rate of proliferative retinopathy of about 20–25% in T1D (Fong, Aiello, & Ferris, 
2004). Retinopathy and neuropathy are unlikely to develop before age 15 years and less than 5 
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years of diabetes duration (Olsen et al., 2000).  A close relationship between diabetic retinopathy 
and nephropathy exists (Klein, Klein, Linton, & Moss, 1992, 2005). Routine screening for 
microvascular complications is generally initiated at 12-15 years of age in children 5 years after 
the onset of T1D. Diabetic neuropathy is rarely reported in children, however screening is 
recommended at the same age as for the other microvascular complications. 
2.3.3 Macrovascular Complications 
Children with T1D have up to a 10-fold higher risk of macrovascular complications in adulthood 
compared to the population with no diabetes (Daneman, 2006).  Risk factors for cardiovascular 
disease in childhood include the presence of microvascular complications, dyslipidemia, 
hypertension, obesity, smoking, and a family history of premature cardiovascular disease 
(Daneman, 2006; Egg-Olefsson et al., 2007; Palta et al., 2009). Presence of childhood 
cardiovascular risk factors have been unequivocally shown to be associated with accelerated 
atherosclerosis (Katzmarzyk et al., 2004; McGill et al., 2002).  The increasing prevalence of 
obesity globally has also affected children with T1D and has led to a rise in associated risk 
factors for macrovascular disease (Krishnan & Short, 2009). Van Vliet and colleagues (2010) 
have shown in a Dutch cohort of 283 children age 3-18 years with a mean duration of diabetes of 
5.3 years, that 38.5% were overweight or obese. Hypertension was found in 13.1% of patients, 
and elevated LDL cholesterol in 17.3%. In a Norwegian study on prevalence of cardiovascular 
risk factors in children with T1D, obesity was less prevalent (4%) but 86% of children had at 
least one cardiovascular risk factor (Margeirsdottir, Larsen, Kummernes, Brunborg, & Dahl-
Jorgensen, 2008). The presence of two cardiovascular risk factors was reported in 14% of 
children with T1D in the SEARCH for diabetes in youth study (Rodriguez et al., 2006).  
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In Canada, the prevalence of overweight and obese children with T1D in Manitoba was 24.7% 
with the highest rate in females age 12-18 years old (38.2%) (2010 Winnipeg Child Health 
Program Annual Report, n.d.). Early detection and management of cardiovascular risk in 
children and young adults with T1D is important. For example, the Epidemiology of Diabetes 
Interventions and Complications study (EDIC), a long term follow up study of the DCCT, 
showed that intensive insulin treatment decreased macrovascular complications in T1D patients 
over the long-term (Nathan et al., 2005). 
2.4    Management of Type 1 Diabetes in Children and 
Adolescents 
  
2.4.1 Rational and Goals  
The primary goal of T1D treatment in children is avoidance of acute and prevention of long term 
diabetes complications. Hypoglycemia and diabetic ketoacidosis (DKA) are serious, potentially 
life threatening acute complications. They are the major cause of mortality and morbidity in 
younger patients with T1D. Sixty-eight percent of diabetes related deaths in children and young 
adults with established T1D are due to hypoglycemia or DKA (Laing et al., 1999). Chronic 
complications, such as nephropathy, neuropathy, or retinopathy are less frequent in pediatric 
population. However, once developed chronic complications are a major contributor to diabetes 
morbidity and mortality (Mathiesen, Hommel, Hansen, Smidt,  & Parving, 1999) and therefore 
prevention is a major focus of diabetes management in adolescents and younger patients with 
longer duration of diabetes.  
Optimal blood glucose control is essential to the prevention of diabetes complications and is the 
major focus of T1D management. 
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2.4.2 Glycemic Targets 
Glycated hemoglobin (A1C) is a test that reflects mean blood glucose levels over the proceeding 
3-4 months. It is a reliable measure of treatment effectiveness and is used to set the target values 
for glucose control (American Diabetes Association [ADA], 2011). These targets are largely 
based on evidence that showed that optimal glycemic control determined by A1C levels 
decreases the risk for diabetes complications. 
 The Diabetes Control and Complications Trail, the largest randomized control trial of different 
glycemic targets in subjects with T1D, demonstrated that strict blood glucose control (mean A1C 
7.2%) was associated with 30-70 % reduced risk of retinopathy, neuropathy, nephropathy, and 
serious cardiovascular outcomes (Nathan et al., 2005). Intensive insulin treatment, defined as 
three or more insulin injections a day or continuous subcutaneous insulin injection (an insulin 
pump), was used in the treatment group to achieve glycemic targets. The DCCT also showed that 
there was no threshold effect as any decrease in A1C concentrations is associated with a decline 
in the relative risk for complications. Furthermore, there is no A1C level below which 
complications are not completely prevented, nor one above which complications are certain to 
develop (Daneman, 2006). This landmark trial included 195 T1D subjects age 13-18 years. As a 
result of this study, there is strong evidence that target A1C levels in adults and in children age 
13-18 years should be <7%. There is no similar level of evidence to assess A1C targets for 
children younger than age 13 years.  
Current CDA Practice Guidelines recommend the following glycemic targets (Table 1): A1C 
<8.5% for children 0–6 years of age,  <8% for those 6–12 years of age, and ≤ 7% for 13-18 years 
of age (CDA Clinical Practice Guidelines Expert Committee, 2008). These recommendations are 
12 
 
 
 
based on the consensus of the Steering and Executive Committees of the CDA. Rigorously 
conducted studies in young children with T1D determining optimal A1C values are limited. The 
main limiting factors are the low incidence of chronic complications in the youngest age groups 
and the particularly high risk of hypoglycemia. For example, in the DCCT adolescent cohort 
there was a 2-4 fold increase in the risk of hypoglycemia in the intensive versus control group 
(DCCT Research Group, 1993). The onset of diabetes at age < 7 years of age has been associated 
with recurrent hypoglycemic episodes and poor cognitive function (Ryan, Gurtunca, & Becker, 
2005). Therefore, treatment goals in young (age <13 years) T1D patients should be 
individualized and aim to achieve a target A1C without recurrent hypoglycemia (CDA Clinical 
Practice Guidelines, 2008). Challenges in determining the A1C target goals in pediatric 
populations are reflected in the different recommended target values across different diabetes 
organizations that publish guidelines across the world (see Section 2.5 Determinants of glycemic 
control). 
In summary, there is a pivotal role of glycemic control in the  management of childhood T1D. 
The glycemic goals of diabetes management in children and adolescents with T1D are based on 
the prevention of acute and/or chronic diabetes complications with age-specific targets also being 
directed by the risk for hypoglycemia.  
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Table 1: Recommended Glycemic Targets for children with T1D 
(2008 Canadian Diabetes Association Practice Guidelines) 
Age (years) A1C (%)* 
< 6 < 8.5 
6-12 < 8.0 
13-18 < 7.0 
                     *A1C – glycated hemoglobin 
2.4.3 Distribution of Glycemic Control 
The level of glycemic control in children with T1D varies worldwide. A mean A1C of 8.6% was 
described in an international study of 2,837 children and adolescents including 22 centers in 
Europe and Asia (Mortensen et al., 1997). The American-based SEARCH for diabetes in youth 
study showed similar results with a mean A1C of 8.18% (Pettiti et al., 2009), while the largest 
study of pediatric T1D patients from Germany and Austria (26,687 children with T1D in 152 
pediatric centers) showed a mean A1C value of 7.6% (Gerstl et al., 2007). In the SEARCH 
study, the percentages of children with A1Cs at target according to age were similar across age 
groups: 44.8% (age<6), 43.6% (age 6-12), and 45.7% (age 13-18) (Pettiti et al., 2009). There are 
fewer studies describing overall level of control in children and adolescents in Canada. In 
Manitoba, the average A1C levels among children 0-10 years was 8.3%, while for children 11-18 
years old the mean value was 8.9% (2010 Winnipeg Child Health Program Annual Report, n.d.). 
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In this study, only 29.7 % of children age < 9 years were at a target A1C level while in two other 
categories, age 10-14 and > 14 years, there were, respectively, 32.6% and 28.5 % children with 
mean A1Cs at target (target A1C < 8.3% for 10-14 years and < 7% for  > 14 years old).  
2.5   Determinants of Glycemic Control 
There is a significant body of literature describing factors associated with glycemic control in 
children and adolescents with T1D. Information about potential determinants of glycemic control 
was initially derived from cross-sectional studies (conducted 15-20 years ago) that explored 
demographic or diabetes-related characteristics out of a number of candidate predictors that 
independently contributed to the improved glycemic control.  The evidence indicated that 
children diagnosed at a younger age, who had longer diabetes duration, lived with one parent and 
belonged to low income families, who checked their blood glucose less frequently and who had a 
higher body weight were less likely achieve the target A1C values (Palta et al., 1996; Dorchy et 
al., 1997; Mortensen et al., 1998; Rosilio et al., 1998; Danne et al., 2001; Craig, Jones, Silink, & 
Ping, 2007).  
Following is a brief summary of determinants of glycemic control in children and adolescents 
with T1D considered in this thesis. These factors are further described in the next chapter (see 
Section 3.3). 
Gender 
Female gender was correlated with worse glycemic control in previous studies (Petitti et al., 
2009; Danne et al., 2001; Gerstl et al., 2007). However, small studies that included a greater 
proportion of prepubertal subjects have not reported gender differences in the glycemic control 
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(Palta et al., 1996; Urbach et al., 2004, Shalitin & Philip, 2011).  Earlier onset of puberty in 
females, differential effect of sex hormones on insulin resistance, and higher prevalence of eating 
disorders in adolescent females are suspected to be responsible for the effect of gender on 
glycemic control (Jones, Lawson, Daneman, Olmsted, & Rodin, 2000; Amiel, Sherwin, 
Simonson, Lauritano, & Tamborlane, 1986). 
Age and Diabetes Duration 
 According to the literature glycemic control worsened as age increased (Rosilio et al., 1998; 
Danne et al., 2001; Urbach et al., 2004;  Petitti et al., 2009). There are multiple factors 
responsible for this complex relationship such as progressive loss of beta cell function in the 
early years of diagnosis, potential weight gain as a result of insulin treatment, insulin resistance 
that develops at adolescence and a myriad of psychosocial factors such as decreasing compliance 
with treatment and diet reported during teenage years (Gordon & Mansfield, 1996; Urbach et al., 
2004; Scholin et al., 2004). Similarly, several studies have demonstrated a pattern of worsening 
glycemic control with increasing diabetes duration (Rosilio et al., 1998; Danne et al., 2001; 
Petitti et al., 2009). 
Distance from the Treatment Center 
Location of a specialized diabetes treatment center correlated with glycemic control in a French 
study (Rosilio et al., 1998). In describing their experience, Rosilio (1998) and colleagues 
demonstrated better glycemic control in the participants who lived closer to the treatment center 
(<50 km). There were no other reports that included information on the managing center 
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location. Other center characteristics (e.g. type, size) were more frequently described in the 
literature (see Section 2.5.4).  
Household Income  
The relationship between socio-economic status (SES) commonly defined as a combination of 
education, income and occupation and glycemic control in children with T1D has not been 
extensively studied. The children and adolescents in the U.S. SEARCH for diabetes study had 
better glycemic control if their average household income was greater than $ 25, 000. Rosilio 
and colleagues (1998) demonstrated the same in a French study. Subjects with poorer glycemic 
control were more likely to have a parent with a monthly income < $ 1, 000 (Rosilio et al., 
1998). The effect of income was independent of ethnicity and parental education in those studies 
(Pettite et al., 2009; McKenney et al., 2008; Rosilio et al., 1998). 
Body Mass Index  
Association of BMI and glycemic control varies across the studies. Worse glycemic control in 
normal and underweight youth with T1D compared to obese subjects was reported in the study 
of Petitte and colleagues (2009). However, increase in BMI was associated with higher A1C 
level in other studies including the study of Cutfield and colleagues (2011).  More studies are 
needed to determine the relationship between BMI levels and achievement of glycemic control in 
children and adolescents with T1D. 
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Previous Control 
Finally, early achievement of good glycemic control is predictive of future glycemic control 
(Cutfield et al., 2011; Viswanathan, Sneeringer, Miller, Eugster, & DiMeglio, 2010). Shalitin et 
al  (2011) reported that in children with T1D diagnosed before age 6.5 years, mean A1C level in 
the first year after diagnosis was a strong predictor of achieving target A1C levels in the 
subsequent years independently of insulin regimen.  
2.5.1 Longitudinal Patterns of Glycemic Control in Children and          
Adolescents and Associated Factors  
More recently, prospective cohort data on predictors of glycemic control in children and 
adolescents with T1D have emerged. In an effort to improve the quality of diabetes care in 
children and adolescents, associations of diabetes centers or study groups (such as the Hvidore 
Study Group, the German Diabetes Quality Control Initiative and the US SEARCH for diabetes 
study group) collected and started publishing longitudinal glycemic outcome data. For example, 
Johannesen and colleagues (2008) compared the changes in glycemic control in a Danish 
diabetic pediatric population between 1996 and 2006. The authors concluded that glycemic 
control improved over the 10 years of follow up and a clear relationship between the  number of 
SMBG and improved control was shown. Glycemic control was significantly associated with 
age, ethnicity and diabetes duration as well. Use of new insulin regimens and insulin analogs was 
not found to improve glycemic control (Johannesen et al., 2008). In Sweden, data from a national 
quality registry was followed prospectively as well. In this study, poor glycemic control was 
associated with older age, high insulin dose, longer diabetes duration, and a higher number of 
visits per year (Hanberger et al., 2008). The US SEARCH study has not yet published 
longitudinal data on predictors of glycemic control. 
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There are only a few other prospective longitudinal studies.  The most recently published study 
of 173 children shows that that factors significantly predicting achievement of the mean target 
A1C (<7.5% as per ISPAD Guidelines) after 6.5 years of follow up were shorter diabetes 
duration and lower A1C levels earlier in the disease (measured at 6 months, 1 and 2 years). 
Gender, ethnicity, age at onset, presence of DKA at onset, mean number of SMBG and type of 
insulin regime were not associated with meeting the A1C target. Mortensen and colleagues 
(1997)  found that glycemic control at 12 months post diagnosis was influenced predominantly 
by ethnicity and the A1C level at the diagnosis (not found in the study of Shalitin and Philip) 
while two other studies have found that female gender and greater BMI were also predictors of 
higher A1C levels (Cutfield et al., 2011; Levine et al., 2001).  
2.5.2 Diabetes Treatment and Predictors of Glycemic Control 
Diabetes treatment related factors such as the number of insulin injections/day, use of an insulin 
pump, insulin dose and type were considered potential determinants of glycemic control as well. 
Interestingly, evidence on the association of glycemic control with type of insulin treatment 
(number of daily injections or injections versus insulin pump) or with daily insulin dose per 
kilogram of body weight have not shown a consistent association (Mortensen et al., 1997, 1998; 
Rosilio et al., 1998; Shalitin &  Philip, 2011). Moreover, the majority of studies have reported no 
correlation of insulin treatment or the daily dose with glycemic control (Mortensen et al., 1998; 
Dorchy et al., 1997; Danne et al., 2001). A weak association between higher insulin doses 
(units/kg body weight), age of puberty, and glycemic control has been seen (Mortensen et al., 
1997; Hanberger et al., 2008; Urbach et al., 2004). De Beaufort and colleagues (2007) reported 
that twice a day insulin regimen improves glycemic control compared to other regimen types 
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including multiple insulin injections and continuous subcutaneous insulin infusion, the funding 
likely explained by the improvement in diabetes education programs.  
2.5.3 Other Variables 
Other variables potentially important in predicting A1C were studied as well. For example, 
Hanberger and colleagues (2008) explored if the higher number of clinical visits was correlated 
with glycemic control and they found significant association. Similarly, Urbach and colleagues 
(2005)  reported higher A1C levels if participants attended the clinic at least 5 times in a year.  
The presence of concomitant conditions such as celiac disease, autoimmune thyroiditis, or 
asthma was not correlated with A1C (DeBeaufort et al., 2007; Shalitin & Philip, 2011). The 
presence of DKA or antibodies at diagnosis also did not correlate with glycemic control (Urbach 
et al., 2005; DeBeaufort et al., 2007; Shalitin & Philip, 2011). 
2.5.4 Summary on the Predictors of Glycemic Control 
In describing the results of the aforementioned studies on predictors of glycemic control, one 
may find that outcome assessment differs across the studies. One of the early studies, the 
International Multicenter study from the Hvidore Study group on Childhood diabetes, defined a 
target A1C< 8% for children age 0-18 years. The cut off value was based on the achieved mean 
A1C in the intensively treated group from the DCCT trial. Other studies, primarily conducted in 
Europe, have defined the target A1C according to the International Society for Pediatric and 
Adolescent Diabetes (ISPAD) Consensus Guidelines (specifically, an A1C< 7.5% for all 
children). Finally, the SEARCH study from the US used the American Diabetes Association 
(ADA) age-specific guidelines similar to the CDA guidelines used in this study (target values for 
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A1C in relation to age are: <8.5% at age < 6 years, < 8.0% at age 6 to 12 years, < 7.5% at age 13 
to 18 years, and < 7.0% at age 19+ years). 
The variation of the findings among the studies emphasizes the complexity of diabetes 
management in children under ‘real-world’ conditions. Risk and fear of hypoglycemia, quality of 
diabetes education, dietary management, and social support are examples of factors influencing 
glycemic control that are more difficult to study and less frequently reported. There is 
convincing evidence that outcomes in children with T1D differ between diabetes centers around 
the world (Mortensen et al., 1998; Daneman, 2009). The Hviodore Study group on Childhood 
diabetes which included 21 pediatric centers from 17 countries in Europe, Japan and North 
America (including the Hospital for Sick Kids in Toronto), examined blood glucose control 
according to the treatment center. A substantial difference in the average A1C levels and the 
rates of hypoglycemia were found between individual centers that was not explained by 
prevailing insulin regimens and rates of hypoglycemia when adjusted for difference in various 
socio-demographic factors (Danne et al, 2001). Craig and colleagues (2006) found a similar 
difference between 96 pediatric centers from Asia and the Western Pacific Region, suggesting 
that significant variability between the centers could be explained by difference in clinical care 
and limited socioeconomic factors. Finally, Rosalio and colleagues (1998) have found that the 
size of the pediatric center providing care to pediatric T1D patients affects diabetes outcomes. 
Patients followed in academic pediatric diabetes centers managing at least 50 new T1D pediatric 
patients a year had a lower mean A1C compared to the patients managed in the centers with 
smaller patient volumes. 
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While the reasons for the different glycemic outcomes across large, specialized, pediatric 
diabetes centers are not entirely clear, it suggests that attitudes of treatment teams, diabetes self-
care, educational models, or patient satisfaction rather than insulin treatment type may be 
responsible for the difference (Danne et al., 2001). This also suggests that determinants of 
glycemic control in children and adolescents with T1D are center specific and it is important to 
study those factors accordingly.  
2.6   Delivery of Diabetes Care 
Diabetes is primarily managed in the outpatient ambulatory setting. Even among the newly 
diagnosed T1D pediatric patients, outpatient management including diabetes education has been 
shown to be less expensive but equivalent or slightly better than inpatient education (Clar, 
Waugh, & Thomas, 2006). The importance of regular, ambulatory diabetes care assessment for 
younger patients with diabetes is essential to maintaining optimal glucose control and to monitor 
for risk factors of acute and chronic complications (Laron et al., 1979; ISPAD Clinical Practice 
Consensus Guidelines, 2009). As described in the previous section, care to a pediatric T1D 
patient should be provided by specialist multidisciplinary diabetes care team consisting of a 
pediatric diabetes specialist, diabetes nurse educator, dietitian, and pediatric social worker. The 
multidisciplinary approach is strongly supported by the results of the DCCT as well (DCCT 
Research Group, 1997). The team should recognize the family and child as an integral part of the 
team. If a child with T1D does not have access to a specialized care center, they should be 
followed by a physician who has access to resources and advice from the specialized team 
(ISPAD Clinical Practice Consensus Guidelines, 2009). Following is the description of the 
regional pediatric diabetes program at the Children’s Hospital, London Health Sciences Centre 
(CH-LHSC). 
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2.6.1 The London Pediatric Diabetes Program 
The CH-LHSC diabetes team provides comprehensive care to over 1,400 children and 
adolescents with diabetes and their families. The majority (95%) of these patients have type 1 
diabetes (T1D) and 60% are adolescents. The multidisciplinary diabetes team is comprised of 3 
pediatric endocrinologists, 3 nurse clinicians, 2 dietitians and 2 social workers with consultation 
from a pediatric psychologist. Diabetes clinics are held twice weekly in the Pediatric Medical 
Day Unit (PMDU) with weekly diabetes team meetings and monthly business meetings. Patients 
are assessed and monitored at both the CH-LHSC and regional outreach clinics.  
The regional pediatric diabetes outreach program was initiated in Sarnia in 1993, extended to 
Chatham in 1997, and then Stratford in 2001. In addition to providing accessible clinical care, 
this program has fostered collaboration and cooperation between the tertiary centre and 
community-based health care professionals and has facilitated development of a collaborative 
infrastructure for clinical research. 
In the last 5 years the number of new patients with T1D referred to the CH-LHSC has ranged 
from 70 to 93 per year.  At diagnosis all patients are seen by one of the three pediatric 
endocrinologists. Patients with new onset T1D in the Stratford area are also referred to the 
tertiary centre for initial management.  Patients with new onset T1D in Chatham and Sarnia are 
initially managed in London and then referred for follow-up to the local outreach clinics. In 2009 
there were 1,688 diabetes outpatient visits at the CH-LHSC and 475 diabetes visits at outreach 
clinics in Chatham, Sarnia and Stratford. 
The Children’s Hospital Diabetes Pump Program was initiated in 1999. The current patient 
population using insulin pump range in age from less than 2 to 18 years old, and comprises 
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approximately 41% of the total diabetes patient population. Patients are also offered the option of 
continuous glucose monitoring and there were 60 insertions for continuous glucose monitoring in 
2009.   
Children and adolescents with T1D are followed every 3 to 4 months at the CH-LHSC and 
outreach clinics by a cohesive team. This provides an excellent opportunity to contact the 
patients and their caregivers about new trials as they arise.  Active research studies are advertised 
in the waiting rooms in the clinic and in a newsletter sent to families every 4 months.  Since 
1987, the Pediatric Diabetes Program has maintained a comprehensive database (Humabase) on 
active T1D patients which has facilitated identification of potential subjects with the required 
criteria for entry to clinical trials. Other initiatives and programs include a summer camp for 
children with diabetes, Children’s Hospital Pediatric Diabetes Newsletter (“Islet Cell News”) for 
children and families with diabetes, insulin pump therapy program, and an education program 
providing workshops and education to families and health professionals in a community.   
2.7   Summary 
The incidence of T1D in children is rapidly increasing such that a doubling of T1D cases 
worldwide is expected in 20 years (IDF, 2012). The rate of diabetes complications remains high 
and, with the increasing incidence, it is becoming clear that the burden of T1D will continue to 
increase.  
While the etiology of T1D remains unknown, insulin therapy is a necessary lifesaving treatment. 
Insulin therapy in combination with other lifestyle measures (diet, frequent home glucose 
checking) is required to achieve strict glycemic control, which decreases the rate of long term 
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diabetes-related complications. However, despite the availability of various insulin treatments, 
this goal remains a challenge.  
Management of diabetes in a pediatric population is complex and it includes interpersonal, 
intrapersonal, community, institutional, and societal factors (Daneman, 2009). A child’s 
cognitive development and abilities, age appropriate development and growth have to be 
considered when treatment goals are set (ADA Clinical Practice Recommendations, 2011). An 
individualized approach to treatment (including considerations such as insulin treatment induced 
hypoglycemia, comorbid conditions, activity and diet) as well as family structure and support, 
early education, availability of services, delivery of diabetes care and support of diabetes 
programs are the major factors to be taken into account (Daneman, 2009). There is a multitude of 
factors to consider when determining glycemic targets in pediatric T1D patients. Understanding 
the factors that predict achievement of the target control is essential. 
 
2.7.1 Research Questions and Objectives  
The goal of this research was to answer the question whether there are demographic and diabetes 
related clinical factors that can predict achievement of the target glycemic control in children and 
adolescents with T1D in Southwestern Ontario.  This was done by addressing the following three 
main objectives: 
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008 
using a regional electronic clinical database for future studies in T1D. 
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Objective 2: To describe and examine social, demographic, and clinical characteristics of this 
cohort. 
Objective 3: To identify factors predictive of glycemic control in the following three age groups: 
< 6 years of age, 6-12 years, and > 12 years of age. 
 
2.7.2 Significance of the Research 
Attaining optimal glycemic control in children and adolescents with T1D is essential, however it 
is difficult to achieve in many patients under ‘real world’ conditions. Improving understanding of 
predictors of optimal glycemic control in the real world is therefore useful. It identifies children 
and youth at highest risk of developing long term diabetes complications. In turn, early and 
targeted intervention toward this group may improve T1D pediatric outcomes.  
Evidence of predictors of glycemic control in children with T1D is limited. In particular, there 
are no studies on determinants of glycemic control in Canada. Our study is the first study in 
Canada to describe predictors of better glycemic control in a geographically defined area served 
by a single specialized pediatric diabetes center.  
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Chapter 3 
3   Methodology 
 
The following chapter will detail the methodology used in this thesis. It begins by providing the 
overview of the data source used to derive the study population and is followed by the theoretical 
framework for this thesis. Next is an explanation of measures and variables defined for this 
study. The chapter will conclude with a brief overview of the statistical analysis used.             
This study is the first step of program research to establish pediatric diabetes research database 
and conduct exploratory analysis using available electronic clinical data. 
3.1   Research Objectives 
The overall goal of our research was to answer the question whether there are demographic and 
diabetes-related clinical factors that can predict achievement of the target glycemic control (as 
measured by the glycated hemoglobin or A1C levels) in children and adolescents with T1D in 
Southwestern Ontario. Three specific objectives were addressed in relation to the research 
question: 
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008 
using a regional electronic clinical database for future studies in T1D 
Objective 2: To describe and examine social, demographic, and clinical characteristics of this 
cohort. 
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Objective 3: To identify factors predictive of glycemic control across three age groups: < 6 years 
of age, 6-12 years, and > 12 years of age. 
3.2   Pediatric Electronic Clinical Database 
Since 1987, the CH-LHSC has employed an electronic clinical record called Humabase. 
Humabase is a stand-alone system (i.e. no data is imported from other administrative, clinical, or 
financial databases) that captures demographic and clinical information about pediatric diabetes 
patients. An administrative assistant enters the data into Humabase directly from the clinical 
notes and laboratory reports recorded at the time of the visit. Humabase produces a clinical 
flowsheet that helps track diabetes care, including processes and outcomes. It is also a 
comprehensive diabetes registry of pediatric diabetes patients in Southwestern Ontario. There are 
1,606 patients currently registered and followed in the Humabase. We have assessed the 
accuracy of the Humabase relative to an existing office patient paper chart in a validation study. 
A random sample of 1% of all clinical encounters was selected and selected diabetes related 
variables were assessed for accuracy of the Humabase. There were 35 variables potentially 
available for validation, and 18 were selected based on their clinical significance. Three levels of 
agreement were used to determine the accuracy, complete, partial and no match.    
We demonstrated high levels of agreement between the Humabase data and reference standard. 
The rate of complete matching ranged from 56-100% with median value of 96.4% completely 
matched data. 
A detailed description of Humabase, its history, data acquisition and validation can be found in 
Appendix A.  
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3.3   Thesis Framework 
We used a literature review on determinants of glycemic control in T1D pediatric population to 
identify demographic and clinical factors that were of interest (Figure 3.1). The following 
variables were included in each model in this thesis: gender, age, distance from the treatment 
center (London), average household income, diabetes duration, body mass index, and previous 
glycemic control.  
Gender 
Glycemic control was shown to differ across gender (Palta et al., 1996; Mortensen et al., 1998). 
Studies have found that female gender was correlated with poorer glycemic control (Petitti et al., 
2009; Danne et al., 2001; Gerstl et al., 2007). In a multicenter study from Austria and Germany 
(included close to 30, 000 participants), females had a higher A1C than males at any age (Gerstl 
et al., 2007). Orchard and colleagues demonstrated that there were gender variations in glucose 
tolerance and insulin response among children and adolescents with T1D (Orchard et al., 1982). 
Selected studies on longitudinal patterns of glycemic control have also reported significant 
association of gender and glycemic control with females exhibiting worse glycemic control 
compared to males. (Daneman et al., 1981, Klein, Slap, Elster, & Schonberg, 1992; Cutfield et 
al., 2011).  
Age 
Studies have demonstrated that age and glycemic control were strongly correlated (Rosilio et al., 
1998; Danne et al., 2001; Petitti et al., 2009). Glycemic control worsened as age increased with 
worst control at pubertal age. This relationship was observed consistently across all studies. It 
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appears that there are multiple factors responsible for this complex relationship including: 
progressive loss of beta cell function in the early years of diagnosis, potential weight gain as a 
result of insulin treatment, insulin resistance that develops at adolescence, and a myriad of 
psychosocial factors such as decreasing compliance with treatment and diet reported during 
teenage years (Mortensen et al., 1996; Gerstl et al., 2007; Daneman, 2006). Palta and colleagues 
(1996) have shown in their study on longitudinal patterns of glycemic control in T1D subjects 
from the Wisconsin Diabetes registry that there was a curvilinear relationship between age and 
A1C. In this study which included 501 T1D subjects age 0-20 followed for up to 4.5 years after 
diabetes diagnosis, the authors included the quadratic age factor but there was no information on 
whether it improved the fit of the prediction model (Palta et al., 1996). Subsequent studies, 
including those with the largest study population to date (Multicenter international Hviodore 
study, multicenter Austrian and German study and Search in Diabetes US study) have all 
assumed a simple linear relationship between age and A1C. In our study, we included age as a 
simple linear term. 
Distance from the Treatment Center 
It has been long recommended that pediatric diabetes care be provided by a specialized center 
(CDA Practice Guidelines, 2008). However, numerous studies have shown that the level of 
glycemic control varied according to location and type of the medical center (Mortensen et al., 
1997; Rosilio et al., 1998; Danne et al., 2001; Hanberger et al., 2008). In a nationwide study in 
France, Rosilio and colleagues (1998) found that glycemic control improved if the family lived 
close (i.e. < 50 km) to the managing center. The subjects included in our study were all part of 
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the same tertiary specialized pediatric diabetes care program at CH-LHSC, but distance of family 
residence to the care center varied between subjects and as such was included as a variable. 
 Household Income 
A cross sectional study in French children demonstrated that A1C <8% was more likely if the 
average monthly family income was > $ 2,000 (Rosilio et al., 1998). In the SEARCH study, 
lower annual household income (< $ 25, 000) was associated with worse glycemic control even 
when adjusted for other variables such as ethnicity and parental education (Petitti et al., 2009). 
Acharya and colleagues (2008) found a negative but statistically non-significant relationship 
between glycemic control and deprivation score (which included income, employment, housing, 
health, education and access). Interestingly in this Scottish study, investigators also examined the 
effect of deprivation scores with postcodes. With each shift per quartile they found that A1C rose 
by 0.2%. Thus, patients living in the least affluent areas had 0.8% higher A1C than those in the 
most affluent area, although this did not reach statistical significance (Acharya et al, 2008). 
Diabetes Duration 
Previous studies demonstrated a positive correlation between diabetes duration and glycemic 
control (Rosilio et al., 1998; Petitti et al., 2009; Danne et al., 2001). An increasing duration of 
diabetes was significantly associated with poorer control demonstrated in a population-based UK 
study of 1,742 children and young people with T1D. The authors of this study reported a 0.08% 
rise in A1C for every additional year of diabetes duration (McKinney et al., 2008). The pattern of 
worsening glycemic control with increased duration of diabetes is due in part to progressive loss 
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of beta cell function but also contributing may be the difficulty in maintaining motivation for 
daily diabetes care over time (Petitti et al., 2009; Scholin et al., 2004). 
BMI 
The children and adolescents in the SEARCH for diabetes in youth study had poorer glycemic 
control if they were classified (<85
th
 percentile) as underweight (Petitti et al., 2009). However, 
Acharya and colleagues (2008) demonstrated improved glycemic control in males and a 
statistically non-significant but similar trend in female T1D participants with lower BMI 
standard deviation scores in a study of 255 T1D subjects in Scotland. BMI was significantly 
associated with glycemic control in the study by Danne and colleagues. Those authors 
demonstrated improved glycemic control with higher BMI (Danne et al., 2001; Hanberger et al., 
2008). It is not yet clear what the relationship between glycemic control and BMI is. Petitti and 
colleagues suggested that in children with lower BMIs, pancreatic beta cell function and insulin 
section were preserved over longer periods and that this favors the negative relationship (Petitti 
et al., 2009). 
Previous Control 
Finally, A1C values at diagnosis and 6 months after diagnosis have been found to be positively 
correlated with the achievement of glycemic control at 24 months post-diagnosis (Shalitin & 
Philip, 2011; Cutfiled et al., 2011). While statistically significant, this relationship was not found 
to be strong. Other reports have described the phenomenon of ‘metabolic tracking’, suggesting 
that earlier achievement of glycemic control may lead to a better control long-term (Edge, James, 
& Shine, 2010).  
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Figure 3.1: Determinants of Glycemic Control  
Demographic variables 
Gender 
Age 
Ethnicity 
 
Clinical variables 
Age at diagnosis 
      Diabetes duration 
      Home blood glucose monitoring 
      Hypoglycemia episodes 
      DKA episodes 
      Previous A1C/glycemic control  
      Insulin regime 
      Insulin dose  
      Pubertal Stage 
      Body Mass Index 
 
Socioeconomic variables 
      Family structure 
      Parental education 
      Household Income 
      Distance from the treatment center 
      Diabetes care center/ provider type 
Outcome variable: A1C 
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3.4 Ethics Approval 
The Western University Health Sciences Research Ethics Board approved this study (Appendix 
B). Only secondary data sources were used in the study and therefore no informed consent was 
required. 
3.5 Study Population 
 
The target population consisted of all pediatric patients (ages 1-20) in the Southwestern Ontario 
region that are diagnosed with Type 1 diabetes mellitus, seen by the specialized pediatric 
diabetes care team at least once and with an A1C measurement entered in the pediatric diabetes 
clinical electronic database.  
We retrospectively examined the Humabase database for the period January 1, 1998 to August 1, 
2008. The start year chosen was the year (1998) when the first Canadian Diabetes Association  
Practice Guidelines which recommended the current model of care were released. The study 
cohort was examined in the 10 years period. Included were patients with permanent residence in 
the Southwestern Ontario area (from Lake Erie to the Bruce Peninsula, which includes Bruce, 
Elgin, Grey, Huron, Middlesex, Norfolk, Oxford and Perth counties). Subjects were followed at 
the tertiary pediatric diabetes program at Children`s Hospital, London Health Sciences Centre as 
well at the two outreach clinics in Sarnia and Stratford. Data is entered centrally at the Children’s 
Hospital in London, where it is stored.  
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3.5.1 Definition of Type 1 Diabetes  
 
Diagnosis and diabetes type were determined by a pediatric endocrinologist and recorded in a 
patient paper chart from which the data were transferred to the Humabase database. The 
diagnosis of T1D was recorded in the Humabase at the time of the patient’s first entry (at the 
diagnosis) in the database.  
3.6   Study Design 
A retrospective cohort study was conducted using the regional pediatric diabetes clinical 
electronic database. All eligible subjects who were entered in the Humabase at the time of 
diabetes diagnosis were identified and followed between 1998 and 2008. Subjects had variable 
length of follow up and were entered in the study at any point over the 10 years of observation. 
Once study participants were identified, the study cohort was stratified into three age groups 
based on age-appropriate glycemic targets of the Canadian Diabetes Association Clinical 
Practice Recommendations (see Table 1).  
The three age strata were treated as the cross sectional subsets. Only the most recent A1C value 
was selected for the analysis. A subject could have been included in each of the three age strata. 
Therefore, each subject contributed between 1 and 3 A1C values that were analyzed separately 
and according to the age category. Subjects’ baseline characteristics were collected at the time of 
the first entry into the database, and while this may precede the study period (i.e. registered prior 
to 1998), it was entered at the time of diagnosis and is as such defined by the study objective. 
The study design is graphically depicted in Figure 2. The circled values are the outcome 
measures (A1C) recorded at the visit and were included in analysis. Non-circled values are A1C 
